Market Overview

UPDATE: Canaccord Genuity Reiterates Hold Rating, Lowers PT on AngioDynamics

Related ANGO
Earnings Scheduled For January 8, 2015
Earnings Scheduled For October 9, 2014
Meet the Next Generation of Medicine (CMXC, ANGO, ONCS) (Small Cap Network)

In a report published Friday, Canaccord Genuity reiterated its Hold rating on AngioDynamics (NASDAQ: ANGO), but slightly lowered its price target from $13.50 to $12.50.

Canaccord Genuity noted, “FQ2 sales were in line, with strong OUS sales offsetting continued US weakness, exacerbated by Hurricane Sandy (~$500-700K). Better-than-expected cost synergies with the Navilyst integration offset a weaker-than-expected GM, leading to an EPS beat despite a higher share count. ANGO generated solid CFO of $11M in FQ2 vs. $2.7M a year ago. While there is evidence the business model is improving, given the status of integration programs and product pipeline, we think the stock could be more attractive in a few quarters' time. We maintain our HOLD rating and lower our target to $12.50 from $13.50.”

AngioDynamics closed on Thursday at $11.18.

Latest Ratings for ANGO

Jul 2014Raymond JamesMaintainsOutperform
Jun 2014Canaccord GenuityUpgradesHoldBuy
Mar 2014Raymond JamesUpgradesMarket PerformOutperform

View More Analyst Ratings for ANGO
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings


Related Articles (ANGO)

Around the Web, We're Loving...

Get Benzinga's Newsletters